Cargando…

Pyroptosis inhibiting nanobodies block Gasdermin D pore formation

Human Gasdermin D (GSDMD) is a key mediator of pyroptosis, a pro-inflammatory form of cell death occurring downstream of inflammasome activation as part of the innate immune defence. Upon cleavage by inflammatory caspases in the cytosol, the N-terminal domain of GSDMD forms pores in the plasma membr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopp, Anja, Hagelueken, Gregor, Jamitzky, Isabell, Moecking, Jonas, Schiffelers, Lisa D. J., Schmidt, Florian I., Geyer, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692205/
https://www.ncbi.nlm.nih.gov/pubmed/38040708
http://dx.doi.org/10.1038/s41467-023-43707-z
_version_ 1785152892994322432
author Kopp, Anja
Hagelueken, Gregor
Jamitzky, Isabell
Moecking, Jonas
Schiffelers, Lisa D. J.
Schmidt, Florian I.
Geyer, Matthias
author_facet Kopp, Anja
Hagelueken, Gregor
Jamitzky, Isabell
Moecking, Jonas
Schiffelers, Lisa D. J.
Schmidt, Florian I.
Geyer, Matthias
author_sort Kopp, Anja
collection PubMed
description Human Gasdermin D (GSDMD) is a key mediator of pyroptosis, a pro-inflammatory form of cell death occurring downstream of inflammasome activation as part of the innate immune defence. Upon cleavage by inflammatory caspases in the cytosol, the N-terminal domain of GSDMD forms pores in the plasma membrane resulting in cytokine release and eventually cell death. Targeting GSDMD is an attractive way to dampen inflammation. In this study, six GSDMD targeting nanobodies are characterized in terms of their binding affinity, stability, and effect on GSDMD pore formation. Three of the nanobodies inhibit GSDMD pore formation in a liposome leakage assay, although caspase cleavage was not perturbed. We determine the crystal structure of human GSDMD in complex with two nanobodies at 1.9 Å resolution, providing detailed insights into the GSDMD–nanobody interactions and epitope binding. The pore formation is sterically blocked by one of the nanobodies that binds to the oligomerization interface of the N-terminal domain in the multi-subunit pore assembly. Our biochemical and structural findings provide tools for studying inflammasome biology and build a framework for the design of GSDMD targeting drugs.
format Online
Article
Text
id pubmed-10692205
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106922052023-12-03 Pyroptosis inhibiting nanobodies block Gasdermin D pore formation Kopp, Anja Hagelueken, Gregor Jamitzky, Isabell Moecking, Jonas Schiffelers, Lisa D. J. Schmidt, Florian I. Geyer, Matthias Nat Commun Article Human Gasdermin D (GSDMD) is a key mediator of pyroptosis, a pro-inflammatory form of cell death occurring downstream of inflammasome activation as part of the innate immune defence. Upon cleavage by inflammatory caspases in the cytosol, the N-terminal domain of GSDMD forms pores in the plasma membrane resulting in cytokine release and eventually cell death. Targeting GSDMD is an attractive way to dampen inflammation. In this study, six GSDMD targeting nanobodies are characterized in terms of their binding affinity, stability, and effect on GSDMD pore formation. Three of the nanobodies inhibit GSDMD pore formation in a liposome leakage assay, although caspase cleavage was not perturbed. We determine the crystal structure of human GSDMD in complex with two nanobodies at 1.9 Å resolution, providing detailed insights into the GSDMD–nanobody interactions and epitope binding. The pore formation is sterically blocked by one of the nanobodies that binds to the oligomerization interface of the N-terminal domain in the multi-subunit pore assembly. Our biochemical and structural findings provide tools for studying inflammasome biology and build a framework for the design of GSDMD targeting drugs. Nature Publishing Group UK 2023-12-01 /pmc/articles/PMC10692205/ /pubmed/38040708 http://dx.doi.org/10.1038/s41467-023-43707-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kopp, Anja
Hagelueken, Gregor
Jamitzky, Isabell
Moecking, Jonas
Schiffelers, Lisa D. J.
Schmidt, Florian I.
Geyer, Matthias
Pyroptosis inhibiting nanobodies block Gasdermin D pore formation
title Pyroptosis inhibiting nanobodies block Gasdermin D pore formation
title_full Pyroptosis inhibiting nanobodies block Gasdermin D pore formation
title_fullStr Pyroptosis inhibiting nanobodies block Gasdermin D pore formation
title_full_unstemmed Pyroptosis inhibiting nanobodies block Gasdermin D pore formation
title_short Pyroptosis inhibiting nanobodies block Gasdermin D pore formation
title_sort pyroptosis inhibiting nanobodies block gasdermin d pore formation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692205/
https://www.ncbi.nlm.nih.gov/pubmed/38040708
http://dx.doi.org/10.1038/s41467-023-43707-z
work_keys_str_mv AT koppanja pyroptosisinhibitingnanobodiesblockgasdermindporeformation
AT hageluekengregor pyroptosisinhibitingnanobodiesblockgasdermindporeformation
AT jamitzkyisabell pyroptosisinhibitingnanobodiesblockgasdermindporeformation
AT moeckingjonas pyroptosisinhibitingnanobodiesblockgasdermindporeformation
AT schiffelerslisadj pyroptosisinhibitingnanobodiesblockgasdermindporeformation
AT schmidtfloriani pyroptosisinhibitingnanobodiesblockgasdermindporeformation
AT geyermatthias pyroptosisinhibitingnanobodiesblockgasdermindporeformation